Asset Details
Do you wish to reserve the book?
Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
Do you wish to request the book?
Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
2016
Overview
Background X‐linked sideroblastic anemia (XLSA) is a disorder characterized by decreased heme synthesis and mitochondrial iron overload with ringed sideroblasts in bone marrow. XLSA is caused by mutations in the erythroid‐specific gene coding 5‐aminolevulinate synthase (ALAS2). Anemia in XLSA is extremely variable, characteristically microcytic and hypochromic with poikilocytosis, and the red blood cell distribution width is increased and prominent dimorphism of the red cell population. Anemia in XLSA patients responds variably to supplementation with pyridoxine. Methods and Results We report four patients with XLSA and three mutations in ALAS2: c.611G>A (p.Arg204Gln), c.1218G>T (p.Leu406Phe) and c.1499A>G (p.Tyr500Cys). The in silico predictions of three ALAS2 mutations and the functional consequences of two ALAS2 mutations were assessed. We performed in silico analysis of these mutations using ten different softwares, and all of them predicted that the p.Tyr500Cys mutation was deleterious. The in vitro prokaryotic expression showed that the p.Leu406Phe and p.Tyr500Cys mutations reduced the ALAS2 specific activity (SA) to 14% and 7% of the control value, respectively. Conclusion In view of the results obtained in this study, a clear relationship between genotype and phenotype cannot be established; clinical variability or severity of anemia may be influenced by allelic variants in other genes or transcription factors and environmental conditions. The different types of anemia are distinguished by characteristic hematological parameters and cellular morphology. The genetic study allows a more precise diagnosis. We report four cases with sideroblastic anemia with mutations in the 5‐aminolevulinate synthase (ALAS2) gene. The in silico analysis of mutations and the in vitro study to assess functional consequences of the two novel mutations, leads to suggest that novel ALAS2 mutations are responsible of the disease.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
